Barclays Upgrades Amgen to Equal-Weight, Raises Price Target to $300
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould upgrades Amgen (NASDAQ:AMGN) from Underweight to Equal-Weight and raises the price target from $230 to $300, indicating a more favorable outlook for the company's stock.
May 03, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's upgrade from Underweight to Equal-Weight by Barclays, along with a significant increase in price target from $230 to $300, reflects a more optimistic view on the stock's future performance.
The upgrade by Barclays, a major financial institution, signals a strong endorsement of Amgen's stock, likely leading to increased investor confidence and potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100